[Recent progress in the treatment of ED small cell lung cancer].
Nokihara
Hiroshi
H
Department of Internal Medicine, National Cancer Center Hospital.
Ohe
Yuichiro
Y
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001549:Benzamides; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D000068877:Imatinib Mesylate; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010879:Piperazines; D011743:Pyrimidines; D014750:Vincristine / Q000008:administration & dosage
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D014750:Vincristine; D005047:Etoposide; D000077146:Irinotecan; D004317:Doxorubicin; D000068877:Imatinib Mesylate; D003520:Cyclophosphamide; C055866:amrubicin; D002945:Cisplatin; D002166:Camptothecin